08:45 AM EDT, 06/06/2024 (MT Newswires) -- HEALWELL AI (AIDX.TO) unit Pentavere Research Group partnered with Takeda Canada to pursue real-world evidence analysis for rare diseases.

The partnership will focus on supporting patients suffering from hereditary angioedema (HAE) with normal C1 inhibitor across Canada. HAE with normal C1 inhibitor is an "ultra-rare" disease characterized by life-threatening recurrent, unpredictable swelling, and does not have any approved treatments.

The lack of real-world data on the prevalence and clinical outcomes of these patients is inhibiting the development of novel therapeutic agents, Healwell says. According to the statement, this collaboration has generated one of the largest cohort datasets globally of hereditary angioedema with normal C1 inhibitor patients.